Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: AMPH stock price vs CPB: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CPB's multiple
Needs CPB P/E.
Implied fair value · at AMPH's multiple
Needs AMPH P/E.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AMPH FY 2025 (ended Dec 31, 2025) · CPB FY 2025 (ended Aug 3, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Amphastar Pharmaceuticals, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
CAMPBELL'S Co · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.79x
1.76x
Net debt / EBITDA
Leverage against operating earnings
1.58x
3.36x
Cash and equivalents
Liquid reserves on the balance sheet
$282.81M
$132.00M
Total debt
Interest-bearing obligations outstanding
$619.71M
$6.86B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BRISTOL MYERS SQUIBB CO
AMPH vs BMY
TEVA PHARMACEUTICAL INDUSTRIES LTD
AMPH vs TEVA
Bausch Health Companies Inc.
AMPH vs BHC
PERRIGO Co plc
AMPH vs PRGO
ANI PHARMACEUTICALS INC
AMPH vs ANIP
COCA COLA CO
AMPH vs KO
PEPSICO INC
AMPH vs PEP
Keysight Technologies, Inc.
AMPH vs KEYS
Mondelez International, Inc.
AMPH vs MDLZ
J M SMUCKER Co
AMPH vs SJM
Lamb Weston Holdings, Inc.
AMPH vs LW
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
